These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24629410)

  • 21. Does cardiovascular phenotype explain the association between diabetes and incident heart failure? The Strong Heart Study.
    de Simone G; Devereux RB; Roman MJ; Chinali M; Barac A; Panza JA; Lee ET; Galloway JM; Howard BV
    Nutr Metab Cardiovasc Dis; 2013 Apr; 23(4):285-91. PubMed ID: 21940153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes.
    Dencker M; Stagmo M; Dorkhan M
    Vasc Health Risk Manag; 2010 Jun; 6():373-82. PubMed ID: 20539839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low prevalence of B-type natriuretic peptide levels < 100 pg/mL in patients with heart failure at hospital discharge.
    Hogenhuis J; Voors AA; Jaarsma T; Hillege HL; Hoes AW; van Veldhuisen DJ
    Am Heart J; 2006 May; 151(5):1012.e1-5. PubMed ID: 16644323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of gamma-glutamyltransferase predict outcome in heart failure with preserved ejection fraction.
    Dalos D; Binder C; Duca F; Aschauer S; Kammerlander A; Hengstenberg C; Mascherbauer J; Reiberger T; Bonderman D
    Sci Rep; 2019 Dec; 9(1):18541. PubMed ID: 31811258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients >70 years of age with heart failure.
    Feola M; Aspromonte N; Canali C; Ceci V; Giovinazzo P; Milani L; Quarta G; Ricci R; Scardovi AB; Uslenghi E; Valle R
    Am J Cardiol; 2005 Sep; 96(5):705-9. PubMed ID: 16125500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.
    McAlister FA; Zheng Y; Westerhout CM; Buse JB; Standl E; McGuire DK; Van de Werf F; Green JB; Armstrong PW; Holman RR;
    Eur J Heart Fail; 2020 Nov; 22(11):2026-2034. PubMed ID: 32621557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort.
    Lejeune S; Roy C; Slimani A; Pasquet A; Vancraeynest D; Vanoverschelde JL; Gerber BL; Beauloye C; Pouleur AC
    Cardiovasc Diabetol; 2021 Feb; 20(1):48. PubMed ID: 33608002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure.
    Greenberg B; Peterson ED; Berger JS; Laliberté F; Zhao Q; Germain G; Lejeune D; Wu JW; Lefebvre P; Fonarow GC
    Clin Cardiol; 2019 Feb; 42(2):277-284. PubMed ID: 30578576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction.
    Anjan VY; Loftus TM; Burke MA; Akhter N; Fonarow GC; Gheorghiade M; Shah SJ
    Am J Cardiol; 2012 Sep; 110(6):870-6. PubMed ID: 22681864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients.
    Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J
    Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations of N-terminal pro-B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study.
    Park M; Vittinghoff E; Shlipak MG; Mishra R; Whooley M; Bansal N
    Am Heart J; 2014 Dec; 168(6):931-9.e2. PubMed ID: 25458658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
    Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
    Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function.
    Mottram PM; Leano R; Marwick TH
    Am J Cardiol; 2003 Dec; 92(12):1434-8. PubMed ID: 14675580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease.
    Nishimura K; Nishimura T; Onishi K; Oga T; Hasegawa Y; Jones PW
    Int J Chron Obstruct Pulmon Dis; 2014; 9():155-62. PubMed ID: 24523584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy.
    Lellouche N; De Diego C; Cesario DA; Vaseghi M; Horowitz BN; Mahajan A; Wiener I; Boyle NG; Fonarow GC; Shivkumar K
    Am J Cardiol; 2007 Jan; 99(2):242-6. PubMed ID: 17223426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abnormal glucose metabolism in acute myocardial infarction: influence on left ventricular function and prognosis.
    Høfsten DE; Løgstrup BB; Møller JE; Pellikka PA; Egstrup K
    JACC Cardiovasc Imaging; 2009 May; 2(5):592-9. PubMed ID: 19442946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic Thresholds for Pre-Diabetes Mellitus and Diabetes Mellitus and Subclinical Cardiac Disease in the General Population:
    Myhre PL; Lyngbakken MN; Berge T; Røysland R; Aagaard EN; Pervez O; Kvisvik B; Brynildsen J; Norseth J; Tveit A; Steine K; Omland T; Røsjø H
    J Am Heart Assoc; 2021 Jun; 10(11):e020447. PubMed ID: 33998259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus.
    Resl M; Clodi M; Neuhold S; Kromoser H; Riedl M; Vila G; Prager R; Pacher R; Strunk G; Luger A; Hülsmann M
    Diabet Med; 2012 Jun; 29(6):721-5. PubMed ID: 22050532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.